# A Study of PER-001 in Participants With Diabetic Retinopathy

> **NCT06003751** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Perfuse Therapeutics, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** PER-001 Intravitreal Implant - Low Dose
- **DRUG:** PER-001 Intravitreal Implant - High Dose
- **DRUG:** PER-001 Intravitreal Implant - Sham

## Key facts

- **NCT ID:** NCT06003751
- **Lead sponsor:** Perfuse Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-05
- **Primary completion:** 2025-04-03
- **Final completion:** 2026-04
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06003751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06003751, "A Study of PER-001 in Participants With Diabetic Retinopathy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06003751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*